Biogen Inc Pre-Recorded Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript
Hello. My name is Laura Nisenbaum, I am the Head of the Diagnostic Pathways Group at Biogen and lead the biomarker strategy for aducanumab. It's my pleasure to present our work on cerebrospinal fluid biomarker concordance with amyloid PET from EMERGE and ENGAGE, our Phase III studies of aducanumab in patients with early Alzheimer's disease.
Before moving into the results from my presentation, I provide here the disclosures from the authors of this work. I want to note that aducanumab is an investigational compound and is not yet approved.
Finally, please note that this presentation may include forward-looking statements as detailed here. The data described in this presentation come from the EMERGE and ENGAGE Phase III aducanumab trials. These studies were identical in design, randomized, 18-month
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
